{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative adjective modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_15092", "batch_size": 260, "batch_pos": 186, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "The segment is a factual report, not using high-potency framing.", "method": "llm_batch", "batch_id": "batch_2_16312", "batch_size": 260, "batch_pos": 157, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "The segment describes research history, not a moderate verb paired with scale/impact.", "method": "llm_batch", "batch_id": "batch_3_17744", "batch_size": 260, "batch_pos": 90, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_16284", "batch_size": 260, "batch_pos": 77, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "The segment reports historical research but lacks explicit calming language.", "method": "llm_batch", "batch_id": "batch_5_11376", "batch_size": 260, "batch_pos": 73, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 6, "answer": "no", "rationale": "The segment does not contain a minimiser used in conjunction with a scale contrast.", "method": "llm_batch", "batch_id": "batch_6_7316", "batch_size": 260, "batch_pos": 38, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"hop_idx": 7, "answer": "uncertain", "rationale": "Missing response from batch", "method": "fallback", "batch_id": "batch_7_6484", "batch_size": 260, "batch_pos": 18, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation.", "method": "llm_batch_retry", "retry": 1, "batch_id": "batch_7_6484_r1", "batch_size": 260, "batch_pos": 18, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 8, "answer": "no", "rationale": "The segment describes research history, not current capability/preparedness.", "method": "llm_batch", "batch_id": "batch_8_17448", "batch_size": 260, "batch_pos": 115, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 9, "answer": "no", "rationale": "The segment describes research origin, not prices or numerical metrics.", "method": "llm_batch", "batch_id": "batch_9_8472", "batch_size": 260, "batch_pos": 208, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 10, "answer": "no", "rationale": "The segment describes the history of research, not speculation about future relief.", "method": "llm_batch", "batch_id": "batch_10_16472", "batch_size": 121, "batch_pos": 27, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 11, "answer": "no", "rationale": "Quote is factual description, not framing language.", "method": "llm_batch", "batch_id": "batch_11_17184", "batch_size": 119, "batch_pos": 25, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 12, "answer": "yes", "rationale": "Factual statement about research history. No explicit framing cues.", "method": "llm_batch", "batch_id": "batch_12_1932", "batch_size": 117, "batch_pos": 23, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
